We are requesting a 5-year competing renewal of our NIDA P30 Center with support for the 6 current Cores (Administrative, Animal, Biochemical Pharmacology, Cell and Immunology, Integrative Pharmacology, and Molecular Biology) and the addition of a seventh, the Database and Drug Interactions Core. Since its inception, the P30 Center has enhanced productivity, synergy, and multidisciplinary research, and enabled the recruitment of new faculty into the field of drugs of abuse. Major integrative themes of our Center include 1) Neuroimmunopharmacology including the study of the effects of drugs of abuse on HIV, 2) Study of drugs of abuse, particularly opioids and cannabinoids, in regulation of inflammation, pain, body temperature, reinforcement, and immune function, and 3) Drug interaction studies which are vital because individuals rarely abuse a single drug. New directions include increased emphasis on cannabinoids and additional studies on the relationship between drugs of abuse and HIV. The scope of the ongoing and future projects in the Center marries in vivo and in vitro approaches that examine effects of drugs at the cellular, biochemical, molecular and whole-organism levels. Integration of information ranging from measurements of behavior to gene activation has stimulated collaborations leading to novel hypotheses and results. The Cores of the P30 Center have fostered multidisciplinary interactions resulting in a true intellectual integration and synergy leading to hypothesis building and implementation of lines of experimentation not previously conceived. The results from the collaborative studies supported by the P30 Cores have been truly innovative. The Center also is a focus for training students, postdoctoral fellows, and junior faculty. Temple University has made major commitments to the Center that will sustain growth in the area of drug abuse research in the future. The Center is the glue that brings together investigators currently funded by NIH or other Federal or non-Federal sources and enhances and extends the effectiveness of research related to drug abuse and addiction in a cost-efficient manner. Cutting edge research being conducted by members of CSAR is supported and enhanced by utilizing the expertise, methodologies, and techniques provided by the Cores.

Public Health Relevance

Drug abuse and addiction continue to be a major public problem with enormous personnel, societal and public health costs. The goal of the P30 Center is to provide cutting-edge resources for investigators to study the impact of drugs of abuse on physiological and pathological processes. The core facilities will enhance and expand the scope of research on drugs of abuse, thus facilitating important scientific discoveries with the overall aim of reducing drug abuse and formulating new important therapeutics.

National Institute of Health (NIH)
National Institute on Drug Abuse (NIDA)
Center Core Grants (P30)
Project #
Application #
Study Section
Special Emphasis Panel (ZDA1-EXL-T (02))
Program Officer
Purohit, Vishnudutt
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Temple University
Schools of Medicine
United States
Zip Code
Ward, Sara Jane; Castelli, Francesca; Reichenbach, Zachary W et al. (2018) Surprising outcomes in cannabinoid CB1/CB2 receptor double knockout mice in two models of ischemia. Life Sci 195:1-5
Liu, Jeffrey J; Sharma, Kirti; Zangrandi, Luca et al. (2018) In vivo brain GPCR signaling elucidated by phosphoproteomics. Science 360:
Oliver, Chicora F; Simmons, Steven J; Nayak, Sunil U et al. (2018) Chemokines and 'bath salts': CXCR4 receptor antagonist reduces rewarding and locomotor-stimulant effects of the designer cathinone MDPV in rats. Drug Alcohol Depend 186:75-79
Zewde, Ashenafi Mebratu; Yu, Frances; Nayak, Sunil et al. (2018) PLDT (planarian light/dark test): an invertebrate assay to quantify defensive responding and study anxiety-like effects. J Neurosci Methods 293:284-288
Rom, Slava; Zuluaga-Ramirez, Viviana; Reichenbach, Nancy L et al. (2018) Secoisolariciresinol diglucoside is a blood-brain barrier protective and anti-inflammatory agent: implications for neuroinflammation. J Neuroinflammation 15:25
Ramirez, Servio H; Andrews, Allison M; Paul, Debayon et al. (2018) Extracellular vesicles: mediators and biomarkers of pathology along CNS barriers. Fluids Barriers CNS 15:19
Brailoiu, Eugen; Barlow, Christine L; Ramirez, Servio H et al. (2018) Effects of Platelet-Activating Factor on Brain Microvascular Endothelial Cells. Neuroscience 377:105-113
Barbe, Mary F; Massicotte, Vicky S; Assari, Soroush et al. (2018) Prolonged high force high repetition pulling induces osteocyte apoptosis and trabecular bone loss in distal radius, while low force high repetition pulling induces bone anabolism. Bone 110:267-283
Gentile, Taylor A; Simmons, Steven J; Barker, David J et al. (2018) Suvorexant, an orexin/hypocretin receptor antagonist, attenuates motivational and hedonic properties of cocaine. Addict Biol 23:247-255
Hicks, Callum; Huang, Peng; Ramos, Linnet et al. (2018) Dopamine D1-Like Receptor Agonist and D2-Like Receptor Antagonist (-)-Stepholidine Reduces Reinstatement of Drug-Seeking Behavior for 3,4-Methylenedioxypyrovalerone (MDPV) in Rats. ACS Chem Neurosci 9:1327-1337

Showing the most recent 10 out of 343 publications